|
Indications and Dosage
Subcutaneous
Diabetes mellitus Adult: Administer 5-10 min before meal. Usual range: 0.5-1 units/kg/day. When used in a meal-related SC inj treatment regimen, insulin aspart may provide 50-70% of total insulin requirement with the remainder provided by an intermediate-acting or long-acting insulin.
|
|
Renal Impairment
Decreased dose may be necessary.
|
|
Hepatic Impairment
Decreased dose may be necessary.
|
|
Administration
Should be taken with food. Administer immediately before meals or soon after meals.
|
|
Contraindications
Hypoglycaemia
|
|
Special Precautions
Renal or hepatic impairment; pregnancy; lactation. Transferring from other insulin. Monitor serum glucose, potassium, electrolytes, HbA1c and lipid profile. Concomitant illness esp infections; hypokalaemia.
|
|
Adverse Reactions
Hypoglycaemia; oedema; pruritus; rash; hypersensitivity reactions; lipoatrophy or lipohypertrophy with SC Inj (rotate Inj site).
|
|
IV/Parenteral/SC: B
|
|
Drug Interactions
Effects may be increased by: oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics. Effects may be decreased by: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium. Signs of hypoglycaemia may be masked by β-blockers, clonidine.
|
|
Action
Description: Insulin aspart, a rapid-acting analog of human insulin, lowers blood glucose levels; it regulates carbohydrate, protein and fat metabolism by inhibiting hepatic glucose production and lipolysis, and enhancing peripheral glucose disposal.
Onset: 0.5 hr. Duration: 3-5 hrs. |
|
MIMS Class
|
Manage Account
Change Password
Sign Out
